- Investing.com
AK006 Breakthrough | Explore Allakos's flagship anti-Siglec-6 monoclonal antibody, AK006, showing promising results in Phase 1 trials for chronic spontaneous urticaria treatment |
Financial Resilience | Delve into Allakos's financial strategy, with a cash runway extending into mid-2026, supporting ongoing clinical development amid market volatility |
Market Dynamics | Analyst targets range from $1.40 to $7.00, reflecting diverse views on Allakos's potential in the competitive CSU treatment landscape |
Strategic Horizons | Learn about Allakos's potential for expansion beyond CSU, leveraging AK006's mechanism to address multiple mast cell-mediated disorders |
Metrics to compare | ALLK | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipALLKPeersSector | |
|---|---|---|---|---|
P/E Ratio | Unlock | NaN | NaN | Unlock |
PEG Ratio | Unlock | NaN | NaN | Unlock |
Price/Book | Unlock | NaN | NaN | Unlock |
Price / LTM Sales | Unlock | NaN | NaN | Unlock |
Upside (Analyst Target) | Unlock | NaN | NaN | Unlock |
Fair Value Upside | Unlock | NaN | NaN | Unlock |